Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Sioux Falls, South Dakota 57105


Purpose:

This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified (DDNOS).


Study summary:

Mental illness affects one in four adults in the United States; approximately 61.5 million Americans experience mental illness in a given year. According to the National Alliance for the Mentally Ill, the impact of serious mental illness costs Americans $193.2 billion in lost earnings per year. In addition, mental illness patients have an increased risk of having chronic medical conditions, leading to increased costs and emergency service utilization for those conditions. In addition to substantial costs, patients with psychiatric illness are difficult to treat. More than two-thirds of patients with depression do not respond to first line therapy. Treatment often involves numerous trials of individual agents and combinations of medications in order to achieve optimal response. Pharmacogenetic testing is being used in more settings to guide treatment decisions.


Criteria:

Inclusion Criteria: - Current primary or secondary diagnosis of Major Depressive Disorder or Depressive Disorder Not Otherwise Specified - Have moderate to severe depression as identified by PHQ-9 scoring of 10 or greater - Taking or be newly prescribed an anti-depressant or anti-psychotic medication - Able to provide informed consent Exclusion Criteria: - Pregnant or breastfeeding - Active and/or unstable diagnosis of substance abuse, excluding nicotine - Primary diagnosis of dementia, bipolar disorder (any type), schizophrenia, schioaffective disorder, or personality disorder


NCT ID:

NCT02443584


Primary Contact:

Principal Investigator
Matthew Stanley, MD
Avera McKennan Hospital & University Health Center


Backup Contact:

N/A


Location Contact:

Sioux Falls, South Dakota 57105
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.